- CFO Spotlights
- Profiles
- Tyler Zeronda
Profile
Tyler Zeronda
Chief Financial Officer, Yarrow Bioscience, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
Tyler Zeronda has been Chief Financial Officer of Yarrow Bioscience, Inc. since July 27, 2026, according to the company's filing of July 28, 2026.1
The filing gives Tyler Zeronda's previous role as Chief Financial Officer and Treasurer at VYNE Therapeutics Inc. (Nasdaq: VYNE).1 Tyler Zeronda joined from outside Yarrow Bioscience, Inc., by the record's reading of the filing.1 The filing shows an earlier chief financial officer seat, so this is not Tyler Zeronda's first.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Yarrow Bioscience, Inc. (VYNE) Pharmaceutical Preparations | Chief Financial Officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- July 27, 2026effective
Yarrow Bioscience, Inc. appointed Tyler Zeronda as Chief Financial Officer, effective July 27, 2026. Profile of Mutya Harsch.
On July 27, 2026, the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the […]
[1] Filing by Yarrow Bioscience, Inc., filed with the SEC on July 28, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Yarrow Bioscience, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 28, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Tyler Zeronda wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.